Treatment Protocol for T-Cell and B-Precursor Cell Lymphoblastic Lymphomaof the European Inter-group Co-operation on Childhood Non-Hodgkin-Lymphoma (EICNHL) - Euro-LB 02

• Conditions: lymphoblastic lymphoma; MedDRA version: 9.1Level: LLTClassification code 10065923Term: Lymphoblastic lymphoma

• Registration Number: EUCTR2007-005396-34-GB
• Lead Sponsor: niversity of Birmingham

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2010-08-31
• Last Update Posted: 19 March 2012

Recruitment & Eligibility

• Status: ot Recruiting
• Sex: All
• Target Recruitment: 173

Inclusion Criteria

?lymphoblastic lymphoma diagnosed either by histomorphological or cytomorphological characterisation
?age < 22 years (i.e. up to but not including the 22nd birthday)
?signed informed consent of patient/parents/guardians for participation
?National and local ethical and regulatory approval of this protocol
?No evidence of pregnancy or breast feeding
?No participation in another clinical study
?Pathological material to be made available for Central Histological Review
?Potential follow up of at least 36 months duration

Are the trial subjects under 18? yes
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range
F.1.3 Elderly (>=65 years) no
F.1.3.1 Number of subjects for this age range

Exclusion Criteria

?HIV infection or AIDS
?severe immunodeficiency
?previous organ transplantation
?previous malignancy
?pre-existing disease prohibiting chemotherapy as per instructions of the Protocol
?previous chemotherapy or radiotherapy
?previous systemic corticosteroid treatment for more than 8 days within two months before the beginning of therapy according to this Protocol EURO-LB 02

Study & Design

• Study Type: Interventional clinical trial of medicinal product
• Study Design: Not specified